FDA gives nod to Valeritas insulin delievery system

The FDA has granted Valeritas 510(k) clearance for its V-Go disposable insulin delivery system to be used in conjunction with the delivery of NovoLog, Novo Nordisk’s fast-acting insulin, a basal-bolus insulin therapy for type 2 diabetics.

The V-Go disposable insulin delivery system is available to deliver 20, 30 or 40 units of insulin in one 24-hour period (0.83 U/hr, 1.25 U/hr or 1.67 U/hr, respectively), according to the Bridgewater, N.J.-based Valeritas. The device can also deliver an on-demand bolus dosing in two unit increments—up to 36 units in a 24-hour time period.

The delivery system weighs an estimated one ounce when filled with insulin and measures 2.3 x 1.3 x 0.5 inches. The system is worn under patient’s clothes.

The system was approved in December 2010 to be used with Eli Lilly’s HumaLog.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.